CD36 and metabolic dysfunction-associated steatotic liver disease: Numerous studies have shown that hepatic CD36 expression and its palmitoylation are significantly up-regulated in MASLD patients and animal models, thereby driving excessive fatty acid uptake and accelerating disease progression [12–14].